Efficacy and safety of adjuvant nivolumab after radical surgery for high-risk urothelial carcinoma: a preliminary report of real-world data from a single institution-Reference-Cited by-同舟云学术

Efficacy and safety of adjuvant nivolumab after radical surgery for high-risk urothelial carcinoma: a preliminary report of real-world data from a single institution

Published:2024-09-12 Issue: Volume: Page:
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Yasuda Yosuke,Numao Noboru,Urasaki Tetsuya,Oki Ryosuke,Oguchi Tomohiko,Fujiwara Ryo,Yoneoka Yusuke,Takemura Kosuke,Yonese Junji,Yuasa Takeshi

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10147-024-02619-8.pdf

Reference24 articles.

1. Alfred Witjes J, Lebret T, Compérat EM et al (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71(3):462–475. https://doi.org/10.1016/j.eururo.2016.06.020

2. Rouprêt M, Seisen T, Birtle AJ et al (2023) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol 84(1):49–64. https://doi.org/10.1016/j.eururo.2023.03.013

3. Stein JP, Lieskovsky G, Cote R et al (2023) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 41(22):3772–3781. https://doi.org/10.1200/jco.22.02762

4. Drakaki A, Pantuck A, Mhatre SK et al (2021) “Real-world” outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma. Urol Oncol 39(1):76.e15-76.e22. https://doi.org/10.1016/j.urolonc.2020.07.011

5. Kagawa H, Urabe F, Kiuchi Y et al (2024) Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study. Int J Clin Oncol 29(1):55–63. https://doi.org/10.1007/s10147-023-02424-9